Introduction
Extrahepatic metastases from hepatocellular carcinoma (HCC) are not so uncommon. [1] [2] [3] The incidence of extrahepatic HCC was reported in 37% of patients, and the frequent sites of metastases are the lung, lymph nodes, and bone. 4 Although most extrahepatic metastases occur in patients at an advanced stage, accurately diagnosing HCC recurrence is necessary to manage the disease and decide the treatment strategy. Furthermore, surgical resection may be effective in selected patients with isolated extrahepatic recurrence of HCC and possibly offers the only chance of long-term survival. [5] [6] [7] [8] [9] [10] Positron emission tomography (PET) with 18 F-fluoro-2-deoxy-d-glucose ( 18 F-FDG) is a useful imaging tool for diagnosis, initial staging, and restaging of a variety of malignancies. 18 F-FDG PET is, however, less successful in the detection of primary HCC because of variable 18 F-FDG uptake in HCC. [11] [12] [13] [14] There have been some reports on the role of 18 F-FDG PET in HCC patients, but its efficiency in detecting extrahepatic metastases from HCC has not been examined. The purpose of this preliminary study was to evaluate the feasibility of 18 F-FDG PET in the detection of extrahepatic metastases from HCC.
Patients and methods

Patients
Among 115 patients admitted to the Second Department of Surgery in Hamamatsu University School of Medicine from October 2000 to July 2002, 16 patients were suspected of having extrahepatic metastases from Background. Positron emission tomography (PET) with 18 F-fluoro-2-deoxy-d-glucose ( 18 F-FDG) is useful in detecting distant metastases from a variety of malignancies. However, its efficiency in detecting distant metastases from hepatocellular carcinoma (HCC) has not been investigated. The aim of this study was to evaluate the usefulness of 18 F-FDG PET for the detection of extrahepatic metastases from HCC. Methods. Nineteen patients suspected of having extrahepatic HCC underwent 18 F-FDG PET. Fourteen patients (group A) had extrahepatic lesions, which were detected by conventional studies. In five patients (group B), conventional imaging showed no extra-or intrahepatic lesions, but the tumor marker levels were elevated. The PET results were compared with those obtained by histopathology or by clinical follow-up. Results. The detection rate of 18 F-FDG PET was 83% (24 of 29 metastases) for extrahepatic metastases larger than 1 cm in greatest diameter and 13% (1 of 8 metastases) for lesions less than or equal to 1 cm. PET revealed two bone metastases not depicted by bone scan, and detected the nodal metastasis and intestinal metastases inconclusive on computed tomography. Extrahepatic lesions were resected in 5 patients of group A on the basis of PET findings. In all patients of group B, PET results were true negative for extrahepatic metastases, but HCCs were detected in the liver within 4 months in 4 patients. These were no falsepositive lesions in either group. Conclusions. This preliminary study suggested that 18 F-FDG PET could provide additional information and contribute to the management of HCC patients suspected of having extrahepatic metastases.
HCC and underwent 18 F-FDG PET. Three patients with HCC who were referred to Hamamatsu Medical Center also had PET examinations to evaluate extrahepatic metastases. Thus, a total of 19 patients (15 men, 4 women; age, 54-79 years; mean age, 69 years) were enrolled in this study.
Our patient population was categorized into two groups according to the motivation for PET examinations. Fourteen patients in group A were suspected of having extrahepatic metastases based on the findings on conventional diagnostic workup. Five patients in group B had elevated levels of alpha-fetoprotein (AFP) and/or des-gamma-carboxy prothrombin (DCP), but no extra-or intrahepatic HCCs were detected by conventional diagnostic workup before the PET examination.
Among the patients in group A, 1 patient had two partial pulmonary resections for pulmonary metastases and a partial jejunal resection for jejunal metastases. He underwent 18 F-FDG PET before each surgery and was examined three times by PET. Thus, a total of 16 PET examinations were performed for the 14 patients of group A. Nine patients developed extrahepatic metastases in the posttreatment course following resection for primary HCC, and 5 patients in the course following trancatheter arterial embolization (TAE). Eleven patients had elevated tumor marker levels, and 3 were within normal limits at the time of PET examination. The cutoff levels of AFP and DCP were set at 20 ng/ml and 40 mAU/ml, respectively.
In group A, a total of 37 extrahepatic metastases were finally diagnosed. The number of lesions for the patient with multiple lung metastases was counted as one site. Nineteen lesions were histopathologically shown to be extrahepatic metastases from HCC by resected specimens, and 18 lesions were diagnosed by clinical and radiologic follow-up. Twelve lesions were located in the lung, 10 in the bone, 9 in lymph nodes, 3 in the small bowel, and 3 in the brain. Eight lesions were less than or equal to 1 cm in greatest diameter and were all located in the lung. Twenty-nine lesions were larger than 1 cm (1.2-6.5 cm)
In group B, although five patients had elevated tumor marker levels at the time of PET examinations, no extra-or intrahepatic recurrence was disclosed in the conventional diagnostic workup conducted within 2 months before PET. Four patients underwent 18 F-FDG PET once, and 1 patient twice, and the time interval between the two PET examinations was 10 months. Three patients underwent PET examination in the posttreatment course following the resection of primary HCC and 2 patients in the course following TAE. The interval between the treatment for primary HCC and the PET examination was 5-34 months (mean, 16 months).
Informed consent for PET examinations was obtained from all participating patients before enrollment in this study.
PET acquisition and interpretation
18
F-FDG PET was performed with a SHR22000 (Hamamatsu Photonics, Hamamatsu, Japan). This system permitted the simultaneous acquisition of 63 axial images of 3.6 mm thickness encompassing a 23-cm axial field of view. Transaxial, coronal, and sagittal images were reconstructed by means of the ordered-subset expectation maximization method with a 128 ϫ 128 matrix. The average reconstructed x-y spatial resolution was about 3-4 mm full-width at half-maximum in-plane.
All patients fasted for at least 5 h before imaging. Serum glucose levels measured at the time of 18 F-FDG injection were less than 122 mg/dl in all patients. Transmission scans were obtained with a germanium-68 external ring source before the intravenous administration of Attenuation-corrected 18 F-FDG PET images were interpreted by the consensus of two experienced nuclear medicine physicians, who were blinded to the results of other imaging procedures. For the semiquantitative analysis, a region of interest (ROI) was drawn over the areas of maximum intensity in each lesion. The ROI data were processed as a standardized uptake value (SUV). Lesions were identified as positive if the accumulation of 18 F-FDG increased relative to a normal contralateral structure or surrounding tissues. No increased activity was considered to be a normal finding. The PET results were compared with those obtained by histopathology or clinical follow-up.
Conventional diagnostic workup
18
F-FDG PET and referential conventional imaging before PET scans were performed within 2 months. All patients underwent a computed tomography (CT) scan or a magnetic resonance imaging (MRI) of the abdomen to evaluate intrahepatic HCC and regional lymph node metastases. Additional conventional diagnostic workup consisted of chest CT (n ϭ 17), bone scintigraphy (n ϭ 9), and an MRI of the brain (n ϭ 2) and spine (n ϭ 2). CT scans were obtained with one of two scanners (CT HiSpeed Advantage or CT ProSeed; GE Medical Systems, Milwaukee, WI, USA) using 10-mm collimation. Dynamic contrast material-enhanced CT was performed to assess intrahepatic lesions after the intravenous administration of nonionic contrast media. MR imaging of the upper abdomen was obtained with a 1.5 T MR system (Signa Horizon EchoSpeed; GE Medical Systems) with a phased-array coil. Gadodiamide hydrate was intravenously administered in the dynamic MR studies.
Bone scintigraphy was performed with 99m
Tchydroxymethyl diphosphonate ([Tc-99m]HMDP; Nihon Mediphysics, Takarazuka, Japan). Anterior and posterior whole-body images were obtained using a dual-head gamma camera (PRISM2000; Phylips, Milpitas, CA, USA) about 3 h after administration of the tracer. Single-photon emission computed tomography was not performed. MRIs of the brain (n ϭ 2) and spine (n ϭ 3) were conducted with 1.5-T superconductive units (Magnetom H15 or Magnetom Symphony; Siemens, Erlangen, Germany). 
Results
Size and sites of metastases
The detection rate of 18 F-FDG PET was 83% (24 of 29 metastases) for extrahepatic metastases larger than 1 cm in greatest diameter and 13% (1 of 8 metastases) for lesions less than or equal to 1 cm in group A (Table 1) . Hypermetabolic lesions were not detected in group B. There were no false-positive lesions in either group. On the patient basis, the sensitivity was 79% (11 of 14 patients in group A), the specificity was 100% (5 of 5 patients in group B), and the accuracy was 84% (16 of 19 patients).
Of 12 lung metastases, 4 lesions were larger than 1 cm in greatest diameter and 8 lesions were less than or equal to 1 cm. 18 F-FDG PET detected 4 lung lesions larger than 1 cm, ranging from 1.2 to 5.0 cm. In terms of lung metastases, the detection rate of PET was 100% (4 of 4 metastases) for lesions larger than 1 cm and 13% (1 of 8 metastases) for those less than 1 cm. Although 1 pulmonary metastasis (patient A-1) was 0.9 cm in size, its accumulation of 18 F-FDG was high enough to be identified on PET image (SUV ϭ 3.8).
The size of ten bone metastases in five patients ranged from 2.5 to 6.5 cm. Four of ten lesions were located in vertebral bodies, three in the ribs, one in the ilium, and one in the scapula. The detection rate of PET was 80% (eight of ten) for bone metastases. Bone scintigraphy failed to identify two bone metastases with positive PET results (patients A-10, A-12) (Fig. 1) . These two lesions were osteolytic metastases with a soft tissue mass and were located in the sacrum and scapula. PET failed to identify two vertebral body metastases (patient A-12; Fig. 2) .
Of nine lymph node metastases, six metastatic lesions were located in regional lymph nodes and three lesions in distant nodes. The size of the nine metastatic nodes ranged from 1.8 to 4.8 cm. The detection rate of 18 F-FDG PET was 100% (nine of nine lymph node metastases) and SUV of the lesions was 4.0-10.3. In patient A-9 with previously irradiated lymph node metastasis, the increase of the 18 F-FDG uptake for the lymph node preceded the regrowth in size (Fig. 3) .
Six of 37 extrahepatic metastases were located in uncommon sites. 18 F-FDG PET detected 3 lesions in the small bowel in patient A-1 (Fig. 4) . 18 F-FDG PET did not detect 3 cerebral metastases from HCC in patient A-5. The patient had previously received radiotherapy for paraaortic lymph node metastasis of hepatocellular carcinoma (HCC). A Fifteen months after radiation therapy, the size of the lymph node had not changed (arrow) and B
18
F-FDG PET showed faint uptake. C Twenty-four months after radiation, the serum DCP level increased to 1830 mAU/ml and the paraaotic lymph node showed a slight increase in size on abdominal CT (arrow). D The uptake of 18 F-FDG in the node remarkably increased (arrow). The lymph node was surgically removed, and the metastasis of poorly differentiated HCC was confirmed
Surgical resection of extrahepatic metastases
Of 14 patients in group A, resection of extrahepatic metastases was indicated for 5 patients because their hepatic disease was well controlled and no other extrahepatic metastases were detected with PET. Tow of the 5 patients had no evidence of recurrent disease after the resection of extrahepatic lesions for 12 and 24 months, respectively. Three patients developed intrahepatic recurrence and/or extrahepatic metastases after initial surgery for extrahepatic metastases, but they survived more than 17 months after surgery.
Course of patients with PET-negative examinations
PET identified no extra-or intrahepatic lesions in five patients in group B. Radiologic follow-up after the PET scan confirmed no extrahepatic metastases at least 14 months after the PET examination. In four patients, tumor marker levels continued to rise after the PET scans. Intense follow-up for these patients, including CT scanning, MRI, or CT with hepatic arteriography, indicated intrahepatic recurrence of the disease 1-4 months after the PET examinations. In one patient, serum AFP levels had fluctuated and clinical follow-up of more than 1 year did not suggest recurrent disease.
Discussion
The detection rate of 18 F-FDG PET was 83% for extrahepatic metastases larger than 1 cm in greatest diameter, suggesting that PET has potential as a useful diagnostic tool for the identification of extrahepatic HCC larger than 1 cm. The limitations of [15] [16] [17] [18] [19] and false-positive accumulation in inflammatory lesions. 20 Poor spatial resolution results in low sensitivity for small lesions. In this study, the detection rate was only 13% for lesions less than or equal to 1 cm. The uptake of 18 F-FDG in well-differentiated tumors is generally low. 13, 16 We could not analyze the relationship between 18 F-FDG uptake and pathological differentiation because the number of lesions examined pathologically was small. There were no false-positive results in this study, and to our knowledge, no study has reported a false-positive rate of PET revealed two bone metastases that were not identified by bone scintigraphy. It is reported that 18 F-FDG PET is more sensitive than bone scintigraphy for the detection of osteolytic bone metastases in patients with breast cancer. 21 As bone metastases from HCC are osteolytic, 22 18 F-FDG PET is expected to be sensitive for the detection of bone metastases from HCC.
PET detected a remarkable increase of 18 F-FDG uptake in lymph node metastasis with minimal change in size that had previously been irradiated. 18 F-FDG PET would be useful to assess the viability of known tumors after radiotherapy or other nonsurgical treatments. PET confirmed intestinal metastases that are not common in HCC. It would have been difficult to definitively diagnose intestinal metastases without the PET result.
Surgical resection is the only therapeutic option offering a chance of long-term survival for patients with extrahepatic metastases. [5] [6] [7] [8] [9] [10] Extrahepatic metastases were resected in five patients on the basis of PET findings. These five patients did not develop extrahepatic metastases within 6 months, and two of five patients are alive without recurrence more than 12 months after resection of extrahepatic metastases. In patients with known extrahepatic lesions, PET may contribute to confirm the presence or absence of distant metastases at other sites and assist in the selection of patients appropriate for surgery.
In conclusion, 18 F-FDG PET could provide additional information to conventional modalities and contribute to the clinical management of HCC patients suspected of having extrahepatic metastases. A further welldesigned study with a large number of patients is needed to confirm the significance of 18 F-FDG PET in detecting extrahepatic metastases from HCC.
